Changing the environment of pancreatic cancer to improve treatment response
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment
This study is looking at ways to change the supportive tissue around pancreatic cancer to help make treatments like chemotherapy and immunotherapy work better for patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Urbana-Champaign NIH-funded |
| Lab location | 1 site (Champaign, United States) |
| Project ID | NIH-10927271 on NIH RePORTER |
What this research studies
This research aims to transform the stroma, or supportive tissue, of pancreatic ductal adenocarcinoma (PDAC) to make it more responsive to chemotherapy and immune therapies. The approach focuses on targeting the coagulation system within the tumor microenvironment, which is known to contribute to the growth and resistance of pancreatic cancer cells. By identifying specific molecular targets related to blood clotting, the researchers hope to enhance drug delivery and reduce the immunosuppressive effects of the tumor environment. This could potentially lead to more effective treatment options for patients with PDAC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with pancreatic cancer by making tumors more sensitive to therapies.
How similar studies have performed: While targeting the tumor microenvironment is a growing area of interest, this specific approach to reprogramming the stroma in PDAC through coagulation targeting is relatively novel and has not been extensively tested.
Where this research is happening
Champaign, United States
- University of Illinois at Urbana-Champaign — Champaign, United States (Active)
Researchers
- Principal investigator: Han, Bumsoo — University of Illinois at Urbana-Champaign
- Study coordinator: Han, Bumsoo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.